| Outcome Measures: |
Primary: Change in serum triglycerides from baseline, With aid of autoanalyser, the investigators will measure the serum triglycerides in blood samples before and after treatment., 12 weeks|Change in blood metabolomics profile of lipid species from baseline, With aid of LC/MS and GC/MS, the investigators will measure blood metabolomics profile of lipid species before and after treatment. The metabolomics measurement will help to detect the profile of all kinds of lipids species. The composition change of all these biological molecular induced by the treatment is our major interest rather than single molecular quantification., 12 weeks | Secondary: Change in serum metabolomics profile of bile acids from baseline, With aid of LC/MS and GC/MS technique, the investigators will measure the blood metabolomics molecular profile of bile acids in blood samples before and after treatment., 12 weeks|Change in serum metabolomics profile of amino acid species from baseline, With aid of LC/MS and GC/MS technique, the investigators will measure the blood metabolomics molecular profile of amino acid species before and after treatment., 12 weeks|Change in Gut microbiome from baseline, With aid of quantitative real-time PCR technique, the investigators will measure gut microbiome in fecal samples before and after treatment., 12 weeks|Change in fasting glucose levels from baseline, With aid of autoanalyser, the investigators will measure fasting glucose levels before and after treatment., 12 weeks|Change in 2-hour postprandial glucose levels from baseline, With aid of autoanalyser, the investigators will measure the 2-hour postprandial glucose levels before and after treatment., 12 weeks|Change in HbA1c from baseline, With aid of HPLC technique, the investigators will measure the HbA1c levels before and after treatment., 12 weeks|Change in Non-HDL-C from baseline, With aid of autoanalyser, the investigators will measure the non-HDL-c levels before and after treatment., 12 weeks|Change in serum total Cholesterol from baseline, With aid of autoanalyser, the investigators will measure serum total cholesterol levels before and after treatment., 12 weeks|Change in serum VLDL-c from baseline, With aid of autoanalyser, the investigators will measure serum VLDL-c levels before and after treatment., 12 weeks|Change in serum HDL-c from baseline, With aid of autoanalyser, the investigators will measure serum HDL-c levels before and after treatment., 12 weeks|Change in serum LDL-c from baseline, With aid of autoanalyser, the investigators will measure serum LDL-c levels before and after treatment., 12 weeks|Change in LDL-C/HDL-C from baseline, The LDL-C/HDL-C will be calculated by the ratio of the LDL-C divided by HDL-C before and after treatment., 12 weeks|Change in serum Apo B from baseline, With aid of autoanalyser, the investigators will measure serum Apo B levels before and after treatment., 12 weeks|Change in serum AST from baseline, With aid of autoanalyser, the investigators will measure serum AST levels before and after treatment., 12 weeks|Change in serum ALT from baseline, In aid of autoanalyser, the investigators will measure serum ALT levels before and after treatment., 12 weeks|Change in serum inflammation markers from baseline, With aid of autoanalyser, the investigators will measure hs-CRP, TNF-alfa, IL-6, and IL-8 etc before and after treatment., 12 weeks|Change in liver fat content from baseline, With aid of ultrasonic diagnostic apparatus, the investigators will measure the fat content in liver before and after treatment., 12 weeks|Change in Ankle-Brachial Index from baseline, The ABI value will be measured by PWV/ABI-form device (OMRON Colin Medical Instruments) before and after treatment., 12 weeks|Change in Brachial-ankle pulse wave velocity from baseline, The baPWV value will be measured by PWV/ABI form device (OMRON Colin Medical Instruments) before and after treatment., 12 weeks|Change in enrichment of fish oil in red blood cell from baseline, With aid of HPLC-ESI-MS/MS, the investigators will measure the enrichment of fish oil in red blood cell before and after treatment, 12 weeks|Pharmacogenomics analysis, With aid of blood DNA genotyping，the investigators will compare the genotype of FASD1,FASD2 and other lipid related candidate genes with the lipid lowering effect of omega-3, 12 weeks
|
